102 related articles for article (PubMed ID: 18724493)
21. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
von Hentig N; Nisius G; Lennemann T; Khaykin P; Stephan C; Babacan E; Staszewski S; Kurowski M; Harder S; Haberl A
Antivir Ther; 2008; 13(8):1039-46. PubMed ID: 19195329
[TBL] [Abstract][Full Text] [Related]
23. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
Justesen US
Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
[TBL] [Abstract][Full Text] [Related]
24. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.
van der Lugt J; Colbers A; Molto J; Hawkins D; van der Ende M; Vogel M; Wyen C; Schutz M; Koopmans P; Ruxrungtham K; Richter C; Burger D;
Antivir Ther; 2009; 14(3):443-50. PubMed ID: 19474478
[TBL] [Abstract][Full Text] [Related]
25. Recall of AIDS drug hits world's poorest patients.
AIDS Read; 2007 Sep; 17(9):439. PubMed ID: 17902224
[No Abstract] [Full Text] [Related]
26. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
[TBL] [Abstract][Full Text] [Related]
27. A mass spectrometry based imaging method developed for the intracellular detection of HIV protease inhibitors.
Dekker LJ; van Kampen JJ; Reedijk ML; Burgers PC; Gruters RA; Osterhaus AD; Luider TM
Rapid Commun Mass Spectrom; 2009 Apr; 23(8):1183-8. PubMed ID: 19283784
[TBL] [Abstract][Full Text] [Related]
28. Favourable use of non-boosted fosamprenavir in patients treated with warfarin.
Honda H; Gatanaga H; Matsumura J; Kamimura M; Goto K; Tsukada K; Honda M; Teruya K; Kikuchi Y; Oka S
Int J STD AIDS; 2009 Jun; 20(6):441. PubMed ID: 19451340
[No Abstract] [Full Text] [Related]
29. FDA notifications. Norvir label changes approved.
AIDS Alert; 2008 Oct; 23(10):115-6. PubMed ID: 18938256
[No Abstract] [Full Text] [Related]
30. Warfarin-antiretroviral interactions.
Liedtke MD; Rathbun RC
Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
[TBL] [Abstract][Full Text] [Related]
31. Darvon manufacturer distributes consumer leaflet.
W V Med J; 1979 Oct; 75(10):xviii. PubMed ID: 294713
[No Abstract] [Full Text] [Related]
32. Preparation and performance evaluation of saquinavir laden cationic submicron emulsions.
Jain V; Prasad V; Jadhav P; Mishra PR
Drug Deliv; 2009 Jan; 16(1):37-44. PubMed ID: 19555307
[TBL] [Abstract][Full Text] [Related]
33. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
Moltó J; Llibre JM; Ribera E; Mínguez C; del Río JS; Pedrol E; Vallecillo G; Cedeño S; Valle M; Miranda C; Negredo E; Clotet B;
J Antimicrob Chemother; 2009 May; 63(5):992-7. PubMed ID: 19279052
[TBL] [Abstract][Full Text] [Related]
34. Anti-HIV agents. Are new drug boosters coming?
TreatmentUpdate; 2009; 21(3):4-5. PubMed ID: 19623726
[No Abstract] [Full Text] [Related]
35. FDA notifications. Alternative dosing regimen for atazanavir is approved.
AIDS Alert; 2008 Nov; 23(11):129-30. PubMed ID: 19048649
[No Abstract] [Full Text] [Related]
36. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
37. The utility of nucleos(t)ide-only regimens in the treatment of Mycobacterium tuberculosis-HIV-1 coinfection.
Armstrong-James D; Menon-Johansson A; Pozniak A
AIDS; 2009 Apr; 23(7):865-7. PubMed ID: 19307940
[TBL] [Abstract][Full Text] [Related]
38. Update on antiretroviral therapy.
Riordan A; Bugembe T
Arch Dis Child; 2009 Jan; 94(1):70-4. PubMed ID: 18838416
[TBL] [Abstract][Full Text] [Related]
39. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles.
Kuo YC; Chen HH
Int J Pharm; 2009 Jan; 365(1-2):206-13. PubMed ID: 18848610
[TBL] [Abstract][Full Text] [Related]
40. Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors.
von Hentig N; Förster AK; Kuczka K; Klinkhardt U; Klauke S; Gute P; Staszewski S; Harder S; Graff J
J Antimicrob Chemother; 2008 Nov; 62(5):1118-21. PubMed ID: 18753189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
